This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
According to a new report from BCC Research, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%.
(PRWEB) July 17, 2014
BCC Research (http://www.bccresearch.com) reveals in its new report, INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%.
iPSCs are a breakthrough technology recognized by the 2012 Nobel Physiology and Medicine Prize. They are expected to bring revolutionary changes to modern medicine and new hope for reprogramming cells to repair damaged tissues in the human body. They are already useful for drug development and modeling of diseases; scientists hope to use them as powerful tools in tissue transplants since they can be developed from a patient's own cells, avoiding the risk of rejection that is often encountered. The technologies of differentiating iPSCs into various tissue cells are also developing rapidly.
Markets and applications for this technology include academic research, drug development and toxicity testing, regenerative medicine, molecular and cellular engineering, cellular reprogramming, and cell culture.
"The clinical research and service iPSCs market is expected to experience rapid growth in the next few years," says BCC Research biotechnology analyst Mike Fan. "Indeed, iPSCs technology is speeding up and improving the drug discovery process, particularly in promoting personal medicine and the development of personalized drugs and diagnostic tests."
iPSCs are artificially derived from non-pluripotent somatic cells by inducing expression of specific genes. Similar to embryonic stem cells, iPSCs possess pluripotency but reduce associated ethical issues by eliminating the use of embryos. Pluripotency refers to the ability to become any tissue in the body, excluding a placenta.
INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS provides an overview of the global market for iPSCs. It includes analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018, as well as profiles of companies important in the industry.
Editors and reporters, who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.
About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dotcom as the source and publisher. Thank you.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12025734.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.